TWST — Twist Bioscience Corporation

Summary of Twist Biosciences Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $110.7 million, up 19.3% year-over-year, marking the 13th consecutive quarter of sequential growth.
• Gross Margin: Improved to 51.6%, a 200 basis point increase from the previous year.
• Adjusted EBITDA: Loss of $13.3 million, an improvement of $1.5 million year-over-year.
• Cash Position: Ended Q2 with $171.7 million in cash and equivalents, down from $197.9 million at the end of Q1 2026.

2. Strategic Updates and Business Highlights

• Growth Drivers: Strong performance in DNA synthesis and Protein Solutions, which grew 28% year-over-year, and NGS applications, which grew 12% year-over-year.
• Partnership with AWS: Announced as a wet lab partner for Amazon BioDiscovery, enhancing capabilities in AI-driven drug discovery.
• Product Development: Continued investment in expanding the DNA synthesis platform, aiming to accept 99.5% of clonal genes and 99.9% of all DNA products, which is expected to drive market share gains.
• Market Segments: Therapeutics revenue rose 55% to $40.8 million, while diagnostics revenue increased 14% to $40 million.

3. Forward Guidance and Outlook

• Fiscal 2026 Revenue Guidance: Increased to $442 million to $447 million, representing a growth of approximately 17% to 19%.
• Q3 Revenue Expectations: Projected to be between $114 million and $115 million, maintaining a growth rate of approximately 19% year-over-year.
• Adjusted EBITDA Breakeven: Expected to be achieved in Q4 2026.

4. Bad News, Challenges, or Points of Concern

• Academic and Government Market: Facing funding pressures, which have led to cautious spending. Although Twist is gaining market share, growth in this segment is slower compared to others.
• Gross Margin Fluctuations: While gross margins improved year-over-year, there was a nominal sequential decline, raising concerns about cost management and operational efficiency.
• Litigation Settlement: A $17.1 million settlement related to a securities class action was reached, which could impact cash flow and management focus.

5. Notable Q&A Insights

• AI-Driven Workflows: AI has significantly contributed to growth, with increasing demand for data characterization and antibody analysis, leading to higher order volumes.
• Sustained Growth Potential: Management expressed confidence in maintaining growth across all segments, particularly in therapeutics and NGS, with broad-based customer engagement.
• Operational Improvements: Plans to enhance automation and workflow efficiency were discussed, with expectations for improved gross margins and operational leverage in the future.

Overall, Twist Biosciences demonstrated strong financial performance and strategic growth initiatives, despite facing challenges in specific market segments and operational efficiency. The company remains optimistic about its future trajectory and market position.